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Orphan drug clinical trials often are adversely affected by a lack of high quality treatment efficacy data that can be
reliably compared across large patient cohorts derived frommultiple governmental and country jurisdictions. It
is critical that these patient data be capturedwith limited corporate involvement. For some time, there have been
calls to develop collaborative, non-proprietary, patient-centric registries for post-market surveillance of aspects
related to orphan drug efficacy. There is anurgent need for thedevelopment and sustainable deployment of these
‘independent’ registries that can capture comprehensive clinical, genetic and therapeutic information on patients
with rare diseases. We therefore extended an open-source registry platform, the Rare Disease Registry Frame-
work (RDRF) to establish an Independent Rare Disease Registry (IRDR).Weengagedwith an established rare dis-
ease community for Gaucher disease to determine system requirements, methods of data capture, consent, and
reporting. A non-proprietary IRDR model is presented that can serve as autonomous data repository, but more
importantly ensures that the relevant data can be made available to appropriate stakeholders in a secure, timely
and efficient manner to improve clinical decision-making and the lives of those with a rare disease.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Orphan drugs are those that are developed to treat specific rare con-
ditions. However, clinical trials for orphan drugs frequently are compli-
cated by a paucity of available patients, heterogeneity in onset, clinical
course and genetic basis, and the scarcity of biomarkers to monitor re-
sponse to therapy. Therapeutic dilemmas, such as the optimal age to
start therapy and dosage at various stages of therapy, therefore, are
often unresolved prior to a drug receivingmarketing approval. Although
regulatory authorities request post-marketing data, this information is
generally only related to safety and is generated by the sponsoring
drug company. Government incentives in the US, Australia and the EU
for orphan drug development have resulted in significant advancement
in the treatments of rare conditions [1]. But, treatment effectiveness
across patient populations has become a contentious issue, with calls
for reform of the post-authorisation assessment of orphan drugs
through adaptive licensing processes [2]. One critical challenge is to ac-
quire high quality treatment efficacy data that can be compared reliably
across patient cohorts, and for rare conditions, typically derived across
governmental and country jurisdictions. Most importantly, these
patient data must be captured with limited corporate interference. As
a result, there has been a call to develop collaborative, industry-
independent, patient-centric registries for post-market surveillance of
aspects related to drug efficacy [2].
The development and sustainable deployment of non-proprietary
Independent Rare Disease Registries (IRDR) will serve as autonomous
data repositories for the collection of comprehensive clinical, genetic
and therapeutic information about patients with rare diseases. A re-
source of this nature has been identified as one of the “key outcomes
from stakeholder workshops at a symposium to inform the develop-
ment of an Australian national plan for rare diseases” [3].
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In late 2014 theWellcome Trust funded a Pathfinder Award to sup-
port and drive the establishment of an IRDR to serve as a model data
source for the collection of comprehensive clinical and genetic rare dis-
ease patient data, and thereby enable the development of target-specific
therapies and clinically differentiated products in the rare disease area.
This was to be achieved through collaboration with expert physicians,
patient organisations and registry development experts. In Australia,
there presently is no national strategy in place for people living with
rare diseases. It is envisaged that one element of a national rare disease
plan should include patient registries and the collection of relevant data
to benefit all stakeholders involved in developing and using innovative
treatments. The creation of an IRDR will serve as a key instrument for
building and empowering rare disease patient communities. Such a reg-
istry would enable all rare disease stakeholders to achieve their differ-
ent but complementary goals aimed at augmenting knowledge and
developing new therapeutic options for the future. As a priority, it was
proposed that the Gaucher registry (GR) would be developed and de-
ployed as the first IRDR.
Several existingdrug registries collect data on the efficacy, treatment
outcomes or toxicity of the three available enzyme replacement thera-
pies; the International Collaborative Gaucher Group (ICGG) Gaucher
Registry (imiglucerase, supported by Genzyme, a Sanofi Company) [4,
5], the Gaucher Disease Enzyme Replacement Therapy Registry
(taliglucerase alfa, supported by Pfizer) [20], and the Gaucher Observa-
tional Study (GOS, velaglucerase alfa, Shire Human Genetic Therapies).
Additionally, several national registries also operate in Spain [7,8],
Brazil [9], and France [6].
For Australian treated patients with Gaucher disease however, man-
ual spreadsheets were kept for all patients, with only one industry-
managed registry available for some data entry (the ICGG Gaucher
Registry). This is not an ideal situation, especially since a single pharma-
ceutical company held the database, even though patients were subse-
quently treated with multiple drugs from different companies. The GR
described in thismanuscript therefore seeks to include all Australian pa-
tients with Gaucher disease, irrespective of treatment status and inde-
pendent of treatment type.
A component of the Pathfinder Award provided for the development
of an IRDR thatwould allow for an increase in knowledge on rare diseases
by pooling data from clinical and epidemiological research and real-life
drug use in communities. This is of particular importance in Australia, a
country that is sparsely populated and has a unique ethnic diversity
with 3% of the population Aboriginal and/or Torres Strait Islander [10],
and28%first generationmigrants fromover 200 countries [11]. Awell im-
plemented IRDR will increase opportunities not only for rare disease
treatments to be developed but also to enable independent post-
marketing review of clinical efficacy and safety. Consistent long-term col-
lection of patient data will help create standards of care (including amin-
imum set of common data elements) that in turn can dramatically
improve patient outcomes and life expectancy, even in the absence of
new therapies. The IRDR would provide unique insight into the detail of
a country's health, social services planning and healthcare organisation.
A recent article byHollak et al. [2] supported the call for independent
registries in Europe. The authors argue that ideally: registries are
disease-centred with data captured from pivotal, extended trials, natu-
ral histories and quality of life studies; they are not drug-centred; ap-
propriate governance and patient data analysis is independent of
corporate influence; mandatory data capture for all doctors treating pa-
tients across Europe; and the launch of registries early in the develop-
ment process of orphan drugs. Thus, there is alignment between the
motivation of theWellcome Trust Award and the requirements outlined
in the article by Hollak et al. [2]
Here we definewhatwe believe are core features of an IRDR and de-
scribe a registry framework that meets these needs, the Rare Disease
Registry Framework (RDRF). The RDRFhas been tailored toGaucher dis-
ease as the model rare disease, for which therapies are available from a
number of drug companies.
2. Materials and methods (registry system overview)
The open source RDRF allows the efficient deployment of web-based
registries that can be modified dynamically as registry requirements
evolve [12–16]. The RDRF employs a modular approach to registry de-
sign that empowers registry administrators to easily configure registries
without software developer effort, by allowingusers to dynamically cre-
ate all data elements (DEs), sections and forms that define a patient reg-
istry and to share DEs across registries. Registries are described in a
computer-readable text file, which allows a registry definition to be
imported/exported, versioned, and stored in a shared accessible envi-
ronment. Multiple registries can also be deployed on a single site, and
patients can be defined once, yet belong to multiple registries.
The RDRF allowsmultiple levels of access, through the dynamic con-
figuration ofworking groups, user groups, and permissions. User groups
may include clinical, genetic, curator and administration users, which
can be configured to have access to different forms and certain registry
functionality. Users are assigned access toworking groups thatmay be a
clinic, state, or country jurisdiction.Users are only able to access the data
of patients who are assigned to theworking groups for which they have
access permission, enabling efficient collaboration for data entry across
jurisdictions (nationally, or internationally).
The RDRF not only facilitates the effective capture, storage, manage-
ment and access of patient information, it is also interoperable with
other systems fromwhich it can capture, import and store data, thereby
integrating patient details with clinical data and results [14]. The ability
to re-use DEs across multiple registries greatly assists in the standardi-
zation of data capture, allowing for effective data sharing for research
purposes.
The RDRF takes a conceptual approach to the design and devel-
opment of patient registries to ensure access, security, privacy,
and to meet the need for harmonisation across multiple clinical
sites in a given country, or internationally. The RDRF also fulfills
the key criteria required for sustainable registry development,
such as open-source, modular design, web-based, provision of an
application programming interface (API), and interoperability [13,
17–19].
We engagedwith an established rare disease community for Gauch-
er disease to determine the system requirements, methods of data cap-
ture, consent, and reporting, and tailored the RDRF to meet these
requirements for the deployment of a Gaucher disease registry.
3. Results and discussion
Through detailed interactions with clinicians, patient advocates and
industry, we identified a significant number of challenges that needed
to be addressed to establish IRDRs. These included: long-term sustain-
ability once a registry is deployed; development and ongoing registry
enhancements; dynamic consent that can be modified once a registry
is deployed; standards for data elements, sections, and forms that can
be shared and which are not hard-coded into the registry; and data
that are not only time-stamped but also captured within a time-
stamped context.
The Rare Disease Registry Framework (RDRF) described in this man-
uscript has an extensive array of features to address these challenges, as
listed in Supplementary Table S1. The key functionality focus of the
RDRFwas to develop a generic IRDRusingGaucher disease as the specif-
ic model, since there are already a number of therapies available for this
condition, with only one international registry open to Australian pa-
tients (the ICGG Gaucher Registry) operating within a single drug com-
pany (Genzyme, a Sanofi Company). The framework for this registry has
been specifically designed for functionality and customisation to be
available at the end-user level rather than at the system development
level. A number of these key features are highlighted in the following
sections.
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3.1. Context
A key requirement for a GR was to enable the capture of data in a
given context. We recognised a subtle but important distinction be-
tween time-stamping data entry in a data field versus time-stamping
data entry according to an assessment date. We refer to the latter
form of time-stamping as a context. For Gaucher Disease the context is
‘Assessment date’. Without this functionality it would be difficult for a
registry system to support post-authorisation assessment. The RDRF
can now support both forms of time-stamping formore general applica-
tion to other diseases. Naturally, analytics and visualisation of patient
data can be conducted more meaningfully at a context level. Fig. 1 pro-
vides details of context.
3.2. Customisable consent
The RDRF has the ability to configure and customise consent (Fig. 2).
From extensive stakeholder engagement it became clear that consent
for a given disease registry is not static and should not be hard-coded
into the registry development. Consent requirements can change, and
individuals may choose to ‘modify’ their consent over time. When ini-
tially designing the consent model, in the RDRF an end-user
Fig. 2. Configurable and customisable consent. a) Consent is now easily customised, with validation and applicability rules available. Time-stamping of when consent is provided in a
searchable table of consent sections. This assists Data Curators to identify patients who have not provided informed consent; b) Further information on individual consent questions
can be obtained by clicking on the patient name.
Fig. 1.Details of context. a) The ‘Patient Listing’ iswhere patients are viewed, and new patients are added by clicking the green ‘add patient’ button. The implementation of ‘context’ allows
new Assessments to be added for each patient, so all data entered into the registry may be viewed (previously only the latest data could be viewed); b) New Assessments are created as
needed. The Demographics and Consent Modules are defined once when the patient is first created, and the collection of Forms are created with each new Assessment; c) New patient
listing page for each individual patient showing all ‘Assessments’ and progress details.
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administering the patient registry is readily able to modify the consent
and can choose to define the required consent validation and applica-
tion rules. For example, consent criteria must all be ‘checked’ or only a
selected ‘mandatory’ number agreed upon. Thus functionality/access
to other functions within a given registry will be determined according
to these rules. Having a digitised patient accessible and modifiable con-
sent will facilitate data-sharing with other researchers to enhance col-
laborative investigations on rare disease cohorts.
3.3. Registry description language
The RDRF employs a description language [14] for all registry defini-
tions. A Registry Mark-up Language (RML) can define a complete regis-
try, a registry form, section, data element, permissible value and
permissible value group. Use of the RML means that a standard registry
definition can be shared. Similarly, definitions for forms, sections and
data elements can be shared. Note that sharing a registry RML is not
sharing the data contained within a given registry. The RML is located
in a shared online environment and can be categorised according to
any given ontology for both registries and data elements. For example,
NINDS define ‘common’ data elements and disease-specific data ele-
ments [21].
3.4. Security and multi-level access
From both application level and operational levels the RDRF sup-
ports an array of security options. From an application level perspective,
the RDRF is built on top of a technology framework that has long-term
support [22]. This framework itself provides distinct levels of built-in se-
curity including: Secure Socket Layer security encrypting all web traffic
to and from the application; Cross-Site Request Forgery checking that is
a method of ensuring that falsification of form submissions is near im-
possible; and login restrictions of all “views”. In addition, the RDRF itself
includes a fully configurable permissions layer (role-based security
model) that restricts the visibility of forms and fields to specified user
groups. Furthermore, the RDRF stores identifying patient contact/demo-
graphic data in a database that is totally distinct from any clinical/genet-
ic data.
From an operational-level perspective, any deployment of a registry
will need to address operational security. This is security relating to the
environment in which the software runs, and cannot be addressed by
the software itself. The registry framework stores data in PostgreSQL
and MongoDB. The databases using these systems are encrypted,
which ensures that data are protected if the storage hardware is (for ex-
ample) stolen, reused, or returned to the manufacturer to address a
fault. In this sense, storage includes all physical media that are used to
store registry data, including the volumes used by the database soft-
ware, the volume on which the front end is installed, and any volumes
used for operating system “swap” space. Communication between the
web interface and the databases is encrypted to guard against confiden-
tial data being intercepted “in transit”.
In terms of physical security, workstations including laptops used to
access the registry should require user authorisation, be subject to ap-
propriate security policies, and have appropriate security software
installed. On any workstation on which reports may be downloaded
from the registry and stored, whole-disk encryption should be imple-
mented on the device to guard against the risk of data exposure through
theft or accidental loss.
3.5. Reporting engine
The RDRF also supports a reporting engine. A user with administra-
tion privileges is able to customise the data contained within the regis-
try to generate a report, which can be configured to be accessed by
certain user groups (Fig. 3). This report template can be saved and
reused as required. The reporting engine also enables various types of
reports to be generated, such as ‘current’ or ‘longitudinal’. While SQL
queries are used to select and aggregate demographic data as required,
simple check boxes for each DE contained in the registry (check for in-
clusion in the report) also enable ease of report construction as they
minimise the use of SQL queries.
3.6. Interoperability
A key feature for any registry is its ability to communicatewith other
registries in a programmatic known as interoperability. The RDRF has
implemented an application programming interface (API) to achieve
this outcome. This API can be used to interrogate other systems, e.g.
other registries or allied systems, such as biobanks, via their APIs. Alter-
natively, if permissions are provided other systems can interrogate a
given registry implemented using the RDRF.
3.7. Sustainability
From our perspective, addressing an IRDR's sustainability is para-
mount. In this regard we consider four important dimensions to an
IRDR sustainability: utility, effectiveness, efficiency and agility. While
the first three dimensions are broadly acknowledged in achieving sus-
tainable solutions in general, we see the fourth dimension as critical
when considering registries. We have previously described patient reg-
istries as non-static entities. Registry requirements, their purpose, func-
tionality, and access privileges evolve over time. For instance, consent,
either from a policy or individual's permission might change, new
data fields reporting new phenotypic measures or refinement of
existing data elements must be catered for, or a registry might initially
be intended as a contact registry with functionality subsequently incor-
porated to convert it to a clinical registry [13].
A sustainable registry must be interoperable with other registries
and to allied systems, such as biobanks and clinical information man-
agement applications, be fit for purpose, yet customisable for end-
users with minimal requirements of software developers. This last
point in particular, is crucial in the facilitation of a sustainable registry
as it dramatically reduces registry maintenance costs without limiting
the flexibility of the system to customise registries. The registry de-
scribed in this paper has been developed to facilitate sustainability
and in this regard it meets each of the criteria listed above.
4. Conclusions
The RDRF has been developed with a focus on sustainability. A
sustainable registry must be able to interoperate efficiently with
other systems via an API. Such systems include other patient regis-
tries, biobanks and clinical information management systems. A
sustainable registry must also be open source, fit for purpose,
customisable for end-users, and by end-users, with minimal in-
volvement of software developers.
The RDRF has an extensive array of features. From our end-user
engagement we have recognised that a number of features that
might be considered bespoke by one rare disease community can,
in fact, be generalised so that these features can become available
to other rare disease communities. The advantage of the RDRF re-
ported in this paper is that it will allow, and include, the incorpora-
tion of data directly reported by patients along with clinical
information reported by healthcare professionals. This will improve
the robustness, comprehensiveness and quality of the data entered.
Furthermore, modular additions, or adjustments to the fields, do
not require high level software input.
The IRDR project will serve as a key instrument for building and
empowering new and existing patient communities, augmenting
knowledge, patient care and developing new therapeutic strategies for
the future. It will facilitate a collaborative approach to the collection of
company independent post-marketing clinical outcome data that will
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rationalise best practice utilisation of orphan drugs. The IRDR will thus
improve decision-making of health care providers at a national level, fa-
cilitating cost-effective programs for the subsidised management of
these extremely expensive drugs.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bcmd.2017.01.013.
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